S. Garofalo

发表

Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergies with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts

L. Racioppi, G. Tortora, F. Ciardiello, 2007 .

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts

G. Fontanini, L. Racioppi, G. Tortora, 2007, Proceedings of the National Academy of Sciences.

A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action

L. Racioppi, G. Tortora, R. Bianco, 2009, Clinical Cancer Research.

Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers

A. Bardelli, A. Scarpa, G. Tortora, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical Toll-like Receptor 9 Agonist IMOCooperateswithCetuximab in KRas Mutant Colorectal and Pancreatic Cancers

F. Nicolantonio, A. Bardelli, A. Scarpa, 2011 .

Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells

A. Ryan, G. Tortora, F. Ciardiello, 2008, Clinical Cancer Research.

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs

G. Tortora, F. Ciardiello, R. Bianco, 2008, British Journal of Cancer.

Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance toAnti ^ Epidermal Growth Factor Receptor Drugs in Human Cancer Cells

A. Ryan, F. Ciardiello, R. Bianco, 2008 .

EGFR-targeting agents in oncology

G. Tortora, R. Bianco, R. Rosa, 2008 .

EGFR-Directed Monoclonal Antibodies

G. Tortora, R. Bianco, T. Gelardi, 2010 .